Jpmorgan Chase & CO Axogen, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AXGN
# of Institutions
163Shares Held
36.6MCall Options Held
230KPut Options Held
400-
First Light Asset Management, LLC Edina, MN4.09MShares$55.1 Million5.0% of portfolio
-
Black Rock Inc. New York, NY3.25MShares$43.8 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.01MShares$40.5 Million3.58% of portfolio
-
Morgan Stanley New York, NY2.9MShares$39.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$32.7 Million0.0% of portfolio
About Axogen, Inc.
- Ticker AXGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 42,283,700
- Market Cap $570M
- Description
- AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...